A61P 7/02
Antithrombotic agents
Official title: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
A61P7/02 (Antithrombotic agents) appears on 9,858 US grants and 12,014 published applications in this corpus.
Search patents in A61P- Granted patents
- 9,858
- Published applications
- 12,014
- Assignees
- 3,486
- Inventors
- 21,655
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 5 | 0 |
| 1977 | 9 | 0 |
| 1978 | 25 | 0 |
| 1979 | 18 | 0 |
| 1980 | 28 | 0 |
| 1981 | 40 | 0 |
| 1982 | 41 | 0 |
| 1983 | 31 | 0 |
| 1984 | 58 | 0 |
| 1985 | 83 | 0 |
| 1986 | 86 | 0 |
| 1987 | 87 | 0 |
| 1988 | 94 | 0 |
| 1989 | 97 | 0 |
| 1990 | 89 | 0 |
| 1991 | 99 | 0 |
| 1992 | 109 | 0 |
| 1993 | 74 | 0 |
| 1994 | 104 | 0 |
| 1995 | 136 | 0 |
| 1996 | 132 | 0 |
| 1997 | 190 | 0 |
| 1998 | 193 | 0 |
| 1999 | 193 | 0 |
| 2000 | 199 | 0 |
| 2001 | 211 | 59 |
| 2002 | 258 | 328 |
| 2003 | 251 | 523 |
| 2004 | 240 | 651 |
| 2005 | 215 | 648 |
| 2006 | 269 | 616 |
| 2007 | 265 | 627 |
| 2008 | 288 | 681 |
| 2009 | 311 | 778 |
| 2010 | 448 | 845 |
| 2011 | 438 | 774 |
| 2012 | 500 | 776 |
| 2013 | 568 | 618 |
| 2014 | 550 | 614 |
| 2015 | 485 | 500 |
| 2016 | 416 | 474 |
| 2017 | 386 | 461 |
| 2018 | 312 | 374 |
| 2019 | 280 | 343 |
| 2020 | 231 | 280 |
| 2021 | 206 | 246 |
| 2022 | 142 | 198 |
| 2023 | 120 | 186 |
| 2024 | 102 | 182 |
| 2025 | 99 | 147 |
| 2026 | 47 | 85 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods for treating drug and vaccine induced immune thrombocytopenia by administering specific compounds6 Oct 2026US 12,751,954 B2Principia Biopharma Inc.
- Peptides and methods of treating sepsis, atherosclerosis, thrombosis, stroke, heart attack and inflammation25 Aug 2026US 12,714,678 B2The Board of Trustees of the University of Illinois
- Aromatic sulphonamides derivatives that inhibits PDI A3, their synthesis and use25 Aug 2026US 12,715,854 B2Uniwersytet Jagiellonski
- Anti-A2AP antibodies and uses thereof25 Aug 2026US 12,715,932 B2Bayer Aktiengesellschaft
- Lyophilized preparation of prostaglandin E1 methyl ester for injection and production and use thereof18 Aug 2026US 12,708,604 B2Xi'an Hanfeng Pharmaceutical Co., Ltd.
- Composition for removing and inhibiting senescent cells, and uses thereof8 Oct 2026US 2026/0306460 A1Lifeceutix Co., Ltd.
- Treatment of clonal hematopoietic disorders using kinase inhibitors8 Oct 2026US 2026/0306462 A1
- Use of milvexian in the treatment and prevention of thrombotic conditions in patients with atrial fibrilation8 Oct 2026US 2026/0306492 A1Bristol-Myers Squibb Company
- Factor xi a2 domain-binding antibodies and methods of use thereof8 Oct 2026US 2026/0308276 A1Regeneron Pharmaceuticals, Inc.
- Adamts13 protein variants and uses thereof8 Oct 2026US 2026/0308560 A1Sanquin IP B.V.
Most cited
By later US patents
- Drug releasing anastomosis devices and methods for treating anastomotic sites1,779US 7,108,701 B2Ethicon, Inc. · 2006
- Solid carriers for improved delivery of active ingredients in pharmaceutical compositions930US 6,248,363 B1Lipocine Inc. · 2001
- Medical device intended to come into contact with a patient's tissue and related manufacturing method849US 8,753,664 B2Perouse Medical · 2014
- Drug loaded polymeric material and method of manufacture829US 5,605,696 AAdvanced Cardiovascular Systems, Inc. · 1997
- Solid carriers for improved delivery of active ingredients in pharmaceutical compositions684US 6,923,988 B2Lipocine Inc. · 2005